# Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

> **NCT01032070** · PHASE2 · TERMINATED · sponsor: **OSI Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Recurrent or Refractory Pediatric Ependymoma

## Interventions

- **DRUG:** erlotinib
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT01032070
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09-27
- **Primary completion:** 2012-11-26
- **Final completion:** 2012-11-26
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, it has been stopped.
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032070, "Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01032070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*